<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial" dtd-version="1.1" specific-use="sps-1.9" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">qQmTtMWXGYJsQs4kBRDCcwt</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S0066-782X2023000200201</article-id>
      <article-id pub-id-type="other">00201</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20220868</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Minieditorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A Hidrata&#231;&#227;o Oral pode ser uma Op&#231;&#227;o na Preven&#231;&#227;o da Nefropatia Induzida por Contraste em Interven&#231;&#245;es Coron&#225;rias Eletivas</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-9631-946X</contrib-id>
          <name>
            <surname>Evora</surname>
            <given-names>Paulo Roberto Barbosa</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina de Ribeir&#227;o Preto</institution>
        <addr-line>
          <named-content content-type="city">Ribeir&#227;o Preto</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Universidade de S&#227;o Paulo &#8211; Faculdade de Medicina de Ribeir&#227;o Preto &#8211; Cirurgia e Anatomia, Ribeir&#227;o Preto, SP &#8211; Brasil</institution>
      </aff>
      <author-notes>
        <corresp id="c01"> Correspond&#234;ncia: Paulo Roberto Barbosa Evora &#8226; Avenida Bandeirantes, 3900, CEP 14049-900, Ribeir&#227;o Preto, SP &#8211; Brasil E-mail: <email>prbevora@gmail.com</email> </corresp>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>27</day>
        <month>02</month>
        <year>2023</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <year>2023</year>
      </pub-date>
      <volume>120</volume>
      <issue>2</issue>
      <elocation-id>e20220868</elocation-id>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
          <license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="pt">
        <kwd>Hidrata&#231;&#227;o/m&#233;todos</kwd>
        <kwd>Nefropatias/preven&#231;&#227;o e controle</kwd>
        <kwd>Hidrata&#231;&#227;o Oral</kwd>
        <kwd>Hidrata&#231;&#227;o Intravenosa</kwd>
        <kwd>Nicorandil/uso terap&#234;utico</kwd>
        <kwd>Cateterismo Card&#237;aco/m&#233;todos</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="5"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>O estudo<sup><xref ref-type="bibr" rid="B1">1</xref></sup> tem perfil editorial question&#225;vel dos ABC Cardiol e n&#227;o apresenta nenhuma novidade. No entanto, sua decis&#227;o de publica&#231;&#227;o &#233; &#250;til para cardiologistas em sua atividade de controle pr&#233;-operat&#243;rio. Sempre se fala em insufici&#234;ncia renal aguda, e &#224;s vezes tem-se a impress&#227;o de que est&#225; sendo subestimada ou superestimada.</p>
    <p>Esses protocolos incluem 1) Medicamentos; 2) alcaliniza&#231;&#227;o com bicarbonato de s&#243;dio, e; 3) hidrata&#231;&#227;o. Dentre as diversas drogas, o nicorandil tem sido utilizado em pacientes com disfun&#231;&#227;o renal cr&#244;nica. Um estudo realizado para avaliar seu efeito preventivo em pacientes de alto risco revelou efic&#225;cia substancial em rela&#231;&#227;o ao protocolo de hidrata&#231;&#227;o para cateterismo card&#237;aco.<sup><xref ref-type="bibr" rid="B2">2</xref> , <xref ref-type="bibr" rid="B3">3</xref></sup> Dentre as diversas drogas, o nicorandil tem sido utilizado em pacientes com disfun&#231;&#227;o renal cr&#244;nica.<sup><xref ref-type="bibr" rid="B4">4</xref> , <xref ref-type="bibr" rid="B5">5</xref></sup></p>
    <p>Concordamos com os autores<sup><xref ref-type="bibr" rid="B1">1</xref></sup> que a medida preventiva mais eficaz at&#233; o momento &#233; a hidrata&#231;&#227;o intravenosa (IV). No entanto, as evid&#234;ncias atuais mostraram que a hidrata&#231;&#227;o oral (HO) &#233; compar&#225;vel &#224; infus&#227;o intravenosa, mas a sua aplica&#231;&#227;o ambulatorial ainda carece de mais investiga&#231;&#245;es em procedimentos coronarianos eletivos.</p>
    <p>O presente protocolo de HO parece ser semelhante ao protocolo de IV hospitalar na prote&#231;&#227;o renal. Os autores sugerem test&#225;-lo em grandes ensaios na tentativa de provar que a HO &#233; eficaz e seria de f&#225;cil ado&#231;&#227;o na pr&#225;tica m&#233;dica.</p>
  </body>
  <back>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1. Pioli MR, Couto RM, Francisco JA, Antoniassi DQ, Souza CR, Olivio MY, et al. Effectiveness of Oral Hydration in Preventing Contrast-Induced Nephropathy in Individuals Undergoing Elective Coronary Interventions. Arq Bras Cardiol. 2023; 120(2):e20220529.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pioli</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Couto</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Francisco</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Antoniassi</surname>
              <given-names>DQ</given-names>
            </name>
            <name>
              <surname>Souza</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Olivio</surname>
              <given-names>MY</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Effectiveness of Oral Hydration in Preventing Contrast-Induced Nephropathy in Individuals Undergoing Elective Coronary Interventions</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2023</year>
          <volume>120</volume>
          <issue>2</issue>
          <elocation-id>e20220529</elocation-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2. Rudnick MR, Fay K, Wahba IM. Fluid administration strategies for the prevention of contrast-associated acute kidney injury. Curr Opin Nephrol Hypertens. 2022 Sep 1;31(5):414-24. doi: 10.1097/MNH.00000000000000815.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rudnick</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Fay</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wahba</surname>
              <given-names>IM</given-names>
            </name>
          </person-group>
          <article-title>Fluid administration strategies for the prevention of contrast-associated acute kidney injury</article-title>
          <source>Curr Opin Nephrol Hypertens</source>
          <year>2022</year>
          <month>09</month>
          <day>1</day>
          <volume>31</volume>
          <issue>5</issue>
          <fpage>414</fpage>
          <lpage>424</lpage>
          <pub-id pub-id-type="doi">10.1097/MNH.00000000000000815</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3. Zaki HA, Bashir K, Iftikhar H, Alhatemi M, Elmoheen A. Evaluating the Effectiveness of Pretreatment With Intravenous Fluid in Reducing the Risk of Developing Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis. Cureus. 2022 May 8;14(5):e24825. doi: 10.7759/cureus.24825.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zaki</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Bashir</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Iftikhar</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Alhatemi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Elmoheen</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Evaluating the Effectiveness of Pretreatment With Intravenous Fluid in Reducing the Risk of Developing Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis</article-title>
          <source>Cureus</source>
          <year>2022</year>
          <month>05</month>
          <day>8</day>
          <volume>14</volume>
          <issue>5</issue>
          <elocation-id>e24825</elocation-id>
          <issue-id pub-id-type="doi">10.7759/cureus.24825</issue-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4. Iranirad L, Hejazi SF, Sadeghi MS, Jang SA. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial. Cardiol J. 2017;24(5):502-7. doi: 10.5603/CJ.a2017.0028.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iranirad</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hejazi</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Sadeghi</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Jang</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial</article-title>
          <source>Cardiol J</source>
          <year>2017</year>
          <volume>24</volume>
          <issue>5</issue>
          <fpage>502</fpage>
          <lpage>507</lpage>
          <issue-id pub-id-type="doi">10.5603/CJ.a2017.0028</issue-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5 Sebasti&#224; C, P&#225;ez-Carpio A, Guillen E, Pa&#241;o B, Arnaiz JA, De Francisco AL, et al. Oral hydration as a safe prophylactic measure to prevent post-contrast acute kidney injury in oncologic patients with chronic kidney disease (IIIb) referred for contrast-enhanced computed tomography: subanalysis of the oncological group of the NICIR study. Support Care Cancer. 2022 Feb;30(2):1879-87. doi: 10.1007/s00520-021-06561-7.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sebasti&#224;</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>P&#225;ez-Carpio</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Guillen</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pa&#241;o</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Arnaiz</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>De Francisco</surname>
              <given-names>AL</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Oral hydration as a safe prophylactic measure to prevent post-contrast acute kidney injury in oncologic patients with chronic kidney disease (IIIb) referred for contrast-enhanced computed tomography: subanalysis of the oncological group of the NICIR study</article-title>
          <source>Support Care Cancer</source>
          <year>2022</year>
          <month>02</month>
          <volume>30</volume>
          <issue>2</issue>
          <fpage>1879</fpage>
          <lpage>1887</lpage>
          <issue-id pub-id-type="doi">10.1007/s00520-021-06561-7</issue-id>
        </element-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn fn-type="other">
        <p>
          <italic>Minieditorial referente ao artigo: Efic&#225;cia da Hidrata&#231;&#227;o Oral na Preven&#231;&#227;o da Nefropatia Induzida por Contraste em Indiv&#237;duos Submetidos a Interven&#231;&#245;es Coron&#225;rias Eletivas</italic>
        </p>
      </fn>
    </fn-group>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Editorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Oral Hydration May Be an Option to Prevent Contrast-Induced Nephropathy in Elective Coronary Interventions</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-9631-946X</contrib-id>
          <name>
            <surname>Evora</surname>
            <given-names>Paulo Roberto Barbosa</given-names>
          </name>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1001">
        <label>1</label>
        <country country="BR">Brasil</country>
        <institution content-type="original">Universidade de S&#227;o Paulo &#8211; Faculdade de Medicina de Ribeir&#227;o Preto &#8211; Cirurgia e Anatomia, Ribeir&#227;o Preto, SP &#8211; Brasil</institution>
      </aff>
      <author-notes>
        <corresp id="c01001">Mailng Address: Paulo Roberto Barbosa Evora &#8226; Avenida Bandeirantes, 3900, Postal Code 14049-900, Ribeir&#227;o Preto, SP &#8211; Brazil E-mail: prbevora@gmail.com</corresp>
      </author-notes>
      <kwd-group xml:lang="en">
        <kwd>Fluid Therapy/methods</kwd>
        <kwd>Nephropathies/prevention and control</kwd>
        <kwd>Oral Hidratation</kwd>
        <kwd>Intravenous Hidratation</kwd>
        <kwd>Nicorandil/therapeutic use</kwd>
        <kwd>Cardiac Catheterization/methods</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>The study<sup><xref ref-type="bibr" rid="B1">1</xref></sup> has a questionable ABC Cardio editorial profile and does not present any novelty. However, its publication decision would be useful for cardiologists in their preoperative control activity. Acute renal insufficiency is always discussed, and sometimes people say it is underestimated or overestimated.</p>
      <p>Many studies support alternative protocols to prevent contrast-induced nephropathy (CIN) caused by iodine contrasts. It is opportune mentioning the safety of ambulatory protocols for vessels and heart exams carried out on the ambulatory &#8220;cath-lab.&#8221;</p>
      <p>These protocols include 1) Drugs, 2) alkalinization with sodium bicarbonate, and; 3) hydration. Among different drugs, nicorandil has been used in patients with chronic renal dysfunction. A trial to assess its preventive effect on high-risk patients revealed substantial efficacy over hydration protocol for cardiac catheterization.<sup><xref ref-type="bibr" rid="B2">2</xref> , <xref ref-type="bibr" rid="B3">3</xref></sup> Among different drugs, nicorandil has been used in patients with chronic renal dysfunction.<sup><xref ref-type="bibr" rid="B4">4</xref> , <xref ref-type="bibr" rid="B5">5</xref></sup></p>
      <p>We agree with the authors<sup><xref ref-type="bibr" rid="B1">1</xref></sup> that the most effective preventive measure to date is intravenous hydration (IVH). However, current evidence shows that oral hydration (OH) is comparable to intravenous infusion. Nevertheless, the effectiveness of ambulatory OH still needs more investigations in elective coronary procedures.</p>
      <p>The OH protocol performed by the patient appears to be like the hospital IVH protocol in renal protection. The authors suggest testing it in large trials in an attempt to prove that OH is effective and would be useful in medical practice.</p>
    </body>
    <back>
      <fn-group>
        <fn fn-type="other">
          <p>
            <italic>Short Editorial related to the article: Effectiveness of Oral Hydration in Preventing Contrast-Induced Nephropathy in Individuals Undergoing Elective Coronary Interventions</italic>
          </p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
